Benefits
No demonstrated effect on muscle protein synthesis
Marketing claims it stimulates muscle protein synthesis without touching hormone pathways. Muscle protein synthesis has never been measured in anyone taking it. It is not hormonally inert: in human prostate cells in the lab it activated the androgen receptor at higher concentrations and blocked it at lower ones. In the only animal test, castrated rats injected daily for 2 weeks gained no muscle at any dose, and at the highest dose several muscles weighed significantly less than in castrated rats given only the injection vehicle.
No anabolic effect found, and not shown to be hormone-free
No study in people or animals has measured testosterone, DHT, estrogen, LH or FSH after taking 5-alpha-hydroxy-laxogenin, so claims that it leaves these hormones untouched rest on nothing. It is also not a legal over-the-counter option in the United States, where the FDA has stated it cannot lawfully be used in dietary supplements. The measured data point the other way: androgen receptor activity in cells, and no anabolic effect in rats.
No evidence of cortisol or anti-catabolic effects
No study in people, animals or cells has tested whether 5-alpha-hydroxy-laxogenin affects cortisol or muscle breakdown. In the only animal study, muscle weights at the highest dose were lower than in castrated rats given only the injection vehicle, not higher.
Mechanism of action
Brassinosteroid theory untested; androgen receptor activity documented
Marketing compares laxogenin to brassinosteroids, plant growth hormones, but no study has shown that 5-alpha-hydroxy-laxogenin acts through any brassinosteroid pathway in animals or people, and plant hormone chemistry is not evidence of an effect in humans. What has been measured: it binds the androgen receptor in computer docking and activates it in human prostate cells at higher concentrations, while blocking it at lower ones. In castrated rats it showed neither androgenic nor anabolic effects, which the researchers suggest may reflect rapid breakdown into other metabolites. A cell-culture study aimed at lab-grown meat reported increased myotube formation at 10 nM, a result in a dish that has not been tested in living muscle.
Clinical trials
Beer C, Keiler AM. Archives of Toxicology, 2022 (Institute of Doping Analysis and Sports Biochemistry Dresden). Two cell-based androgen bioassays. No human trial of laxogenin or 5-alpha-hydroxy-laxogenin has been published.
In vitro only (laboratory cells, not people or animals). Two cell-based bioassays: (1) yeast androgen screen (no activity observed); (2) human PC3(AR) prostate cells with luciferase reporter (dose-dependent androgen receptor transactivation, biphasic response). Not a human or animal in-vivo study. No human study of laxogenin or 5-alpha-hydroxy-laxogenin has been published.
No androgenic activity in the yeast androgen screen. In human PC3(AR) prostate cells, 5-alpha-hydroxy-laxogenin blocked the androgen receptor at lower concentrations and activated it at higher concentrations. The authors concluded that these androgenic properties call for study of its safety and potential anabolic effects, given the risk of doping abuse. A cell result cannot show muscle gain in people, and a later rat study by the same group found no anabolic effect. Regulatory status: the FDA has stated it is not a lawful dietary ingredient in the United States, and it is on the US Department of Defense Prohibited Dietary Supplement Ingredients list.